Amarin Corp Plc (AMRN)

[ziploc_1]

In retrospect, I feel that the replacement of Berg for Holt was a strategic one...Berg was more familiar with the U.S. market...and, in the near term, the U.S. market is going to require a lot more attention due to the new policy of CVS/Caremark to infringe on Amarin's Vascepa CVD patent in favor of generic V....It has been mentioned that Holt's leaving and the dropping of Vascepa by the Caremark PBM are linked...and I agree.

Both KM and Holt were hired for their experience in Europe...and the results have not as excellent as expected.